oppies, page-21

It seems pretty clear to me that the company has enough cash to see them well past the release of the trial results.

As at the end of september we had $978k in the bank and cash outflows have been around $400k per month.

I would note 3 things:

1. The continued improvement in West Coast surgical will improve the operating cash flow performance in Q4 and Q1 next year
2. The trial result collation/report writing costs (ie Q4 costs) IMO would roughly equal the peak patient dosing costs seen in Q2/Q3
3. There will be no trial costs in the next quarter (ie Q1 next year).

So IMO the company has more then enough cash to see them through till the end of March next year, which means there is more than enough time to raise some cash following the release of the trial results and the resultant and expected share price rise.